DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast
Some of the key facts of the Fabry Disease Market Report:
The Fabry Disease market size was valued ~USD 1,306 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In December 2024, Exegenesis Bio, a global clinical-stage gene therapy company, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to EXG110, an innovative gene therapy for Fabry disease—a rare lysosomal disorder characterized by excessive lipid accumulation in tissues, leading to renal failure, cardiac complications, and strokes.
In 2022, the U.S. had the largest Fabry Disease market size among the 7MM, valued at approximately USD 625 million, with projections for further growth by 2032
Within the European Union, the United Kingdom and Italy represent the largest market shares, with figures reaching USD 158 million and USD 150 million respectively in 2022. Conversely, Spain holds the lowest market position during the same period, with a recorded figure of USD 44 million.
In 2022, the Fabry Disease market size reached its peak in the US among the seven major markets (7MM), amounting to approximately USD 625 million. This figure is projected to continue rising through to 2032.
In 2022, there were a total of 15,290 diagnosed prevalent cases of Fabry Disease in the seven major markets (7MM), with the highest number of cases recorded in the United States. The EU4 countries and the UK accounted for 5,245 cases, while Japan had 1,690 cases.
In the US, 4,345 males and 4,011 females were affected by Fabry disease in 2022. These numbers are expected to rise by 2032.
In 2022, the UK had the highest number of diagnosed prevalent cases of Fabry Disease among the EU4 and the UK, with approximately 58% of the cases being female and 42% male. These numbers are anticipated to change during the forecast period.
DelveInsight analysts reported that the diagnosed prevalent cases of Fabry Disease in 2022 were categorized into classic and late-onset phenotypes. There were 3,342 cases of the classic phenotype and 5,013 cases of the late-onset phenotype in the seven major markets (7MM).
Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others
Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others
The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States
The Fabry Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.
Fabry Disease Overview
Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, which leads to a deficiency or malfunction of the enzyme alpha-galactosidase A. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3) in the body’s cells. When alpha-galactosidase A is deficient or dysfunctional, Gb3 accumulates in various tissues and organs, leading to a wide range of symptoms.
Get a Free sample for the Fabry Disease Market Report:
https://www.delveinsight.com/report-store/fabry-disease-market
Fabry Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Fabry Disease Epidemiology Segmentation:
The Fabry Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Fabry Disease
Prevalent Cases of Fabry Disease by severity
Gender-specific Prevalence of Fabry Disease
Diagnosed Cases of Episodic and Chronic Fabry Disease
Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast
Fabry Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Fabry Disease Therapies and Key Companies
ELFABRIO (PRX-102): Chiesi and Protalix Biotherapeutics
Venglustat: Sanofi Genzyme
Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics
PRX-102: Protalix Biotherapeutics
AVR-RD-01: AVROBIO
ST-920: Sangamo Therapeutics
FLT190: Freeline Therapeutics
4D-310: 4D Molecular Therapeutics
Lucerastat: Idorsia Pharmaceuticals
Moss-aGal: Greenovation Biotech GMBH
PRX-102: ICON plc
pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.
migalastat: Amicus Therapeutics
Agalsidase alfa: Shire
Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market
Fabry Disease Market Strengths
Emphasis on NBS to detect Fabry Disease at an early stage allows for timely treatment with better risk- benefit assessment.
The growing Fabry Disease pool is expected to propel the treatment market, adding opportunities for new pharma players.
Fabry Disease Market Opportunities
Development of potential biomarkers allows tracking the severity and predicting the progression of the disease, as well as checking the effectiveness of therapeutic intervention.
The shortcomings of enzyme replacement therapy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches.
Scope of the Fabry Disease Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others
Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies
Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement
To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Fabry Disease Market Report Introduction
2. Executive Summary for Fabry Disease
3. SWOT analysis of Fabry Disease
4. Fabry Disease Patient Share (%) Overview at a Glance
5. Fabry Disease Market Overview at a Glance
6. Fabry Disease Disease Background and Overview
7. Fabry Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Fabry Disease
9. Fabry Disease Current Treatment and Medical Practices
10. Fabry Disease Unmet Needs
11. Fabry Disease Emerging Therapies
12. Fabry Disease Market Outlook
13. Country-Wise Fabry Disease Market Analysis (2019–2032)
14. Fabry Disease Market Access and Reimbursement of Therapies
15. Fabry Disease Market Drivers
16. Fabry Disease Market Barriers
17. Fabry Disease Appendix
18. Fabry Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
